Main Article Content

Ali Taher


iron overload, iron chelation therapy, transfusion dependent thalassemia, non-transfusion dependent thalassemia, serum ferritin, liver iron concentration, deferasirox


Thalassemia incorporates a broad clinical spectrum characterized by decreased or absent production of normal hemoglobin leading to decreased red blood cell survival and ineffective erythropoiesis. Chronic iron overload remains an inevitable complication resulting from regular blood transfusions (transfusion-dependent) and/or increased iron absorption (mainly non-transfusion-dependent thalassemia), requiring adequate treatment to prevent the significant associated morbidity and mortality. Iron chelation therapy has become a cornerstone in the management of thalassemia patients, leading to improvements in their outcome and quality of life. Deferasirox, an oral iron chelating agent is approved for use in transfusion dependent and non-transfusion-dependent thalassemia and has shown excellent efficacy in this setting. We herein present an updated review of the role of deferasirox in thalassemia, exploring over a decade of experience, which has documented its effectiveness and convenience; in addition to its manageable safety profile.

Keywords: iron overload, iron chelation therapy, transfusion-dependent thalassemia, non-transfusion dependent thalassemia, serum ferritin, liver iron concentration, deferasirox


Download data is not yet available.

Abstract 1863
PDF Downloads 1198
HTML Downloads 134


1. Rachmilewitz E and Giardina P. How I treat thalassemia. Blood 2011; 118 (13): 3479-3487.
2. Giardina P, Forget B. Thalassemia syndromes. In: Hoffman R, Benz E, Shattil S, et al, eds. Hematology: Basic Principles and Practice (5th ed). Philadelphia, PA: Churchill Livingstone; 2008:535-563.
3. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010; 115 (22):4331-4336.
4. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006; 91(10): 1343-1351.
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850:227–31.
6. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program 2017; 2017(1):265-71.
7. Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology (Amsterdam, Netherlands). 2015;20(5):311-2.
8. In: rd, Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia (CY): Thalassaemia International Federation (c) 2014 Thalassaemia International Federation.; 2014.
9. Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. American journal of hematology. 2010;85(4):288-90.
10. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124-9.
11. Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol. 2010;2010:358283.
12. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-9.
13. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-33.
14. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3.
15. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-44.
16. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-8.
17. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016;172(4):512-23.
18. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with beta thalassemia intermedia. Blood Cells Mol Dis. 2011;47(4):232-4.
19. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101.
20. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114(1):181-6.
21. Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586.
22. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329–332).
23. Cheng HL, Holowka S, Moineddin R, et al. Liver iron overload assessment by t *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. Am J Hematol. 2012;87(4):435–437.
24. Kirk P, Roughton M, Porter JB, et al. Cardiac t2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–1968.
25. Aubart M, ou P, Elie C et al. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major. J Pediatr Hematol Oncol 2016; 38: 497-502.
26. Porter J, Elalfy M, taher A et al. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. Eur J Hematol 2016; 98: 280-288.
27. Saliba A, El Rassi F, Taher A. Clinical monitoring and management of complications related to chelation therapy in patients with ?-thalassemia. Expert Review of Hematology, 9:2, 151-168.
28. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008; 9(13): 2391-2402.
29. Nick H. Deferasirox (Exjade®, ICL670) Preclinical overview. Semin Hematol .2007; 44: S12-15.
30. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009; 82(6): 454-457.
31. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010; 38(5): 808-816.
32. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003; 10(12):1065-1076.
33. Tanaka C. Clinical Pharmacology of Deferasirox. Clin Pharmacokinet (2014) 53:679–694.
34. Lu M, Lin T, Chiang P, et al. Deferasirox–Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in b-Thalassemia Major. The Drug Monit 2017; 39: 185-191.
35. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
36. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6): 458-465.
37. Taher A, Elalfy MS, Kusai AZ, et al. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with ?-thalassemia: results from the ESCALATOR study.Eur J Haematol. 2011; 87(4):349-354.
38. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (icl670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107 (9):3455–3462.
39. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011; 118(4): 884-893.
40. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective epic study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566.
41. Porter JB, Elalfy MS, Taher AT, et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the epic magnetic resonance imaging substudy. Ann Hematol. 2013;92(2):211–219.
42. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011;141(4):1202-1211, 1211.e1201-1203.
43. Maggio A, Filosa A, Vitrano A et al. Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases 2011; 47: 166–175.
44. JaiSwal S, Hishikar R, Khandwal O et al. Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients. Journal of Clinical and Diagnostic Research. 2017 Feb, Vol-11(2): FC01-FC03.
45. Vichinsky E, El-Beshlawy A, AlZoebie A et al. Long term safety and ef?cacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST). PediatrBloodCancer.2017;64:e26507.
46. Bollig C, Schell LK, Rücker G et al. Deferasirox for managing iron overload in people with Thalassaemia. Cochrane Database of Systematic Reviews 2017(8): 1-216.
47. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica 2011; 96:1055–8.
48. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial t2* in patients with beta-thalassemia major. Haematologica. 2012;97(6):842–848.
49. Pennell DJ, Porter JB, Piga A, et al. A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with ?- Thalassemia Major and Iron Overload (CORDELIA). Blood 2012;121(21).
50. Ho P J, Tay L, Teo J et al. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haem 2016; 9: 9-105.
51. Poggi M, Sorrentino F, Pugliese P et al. Longitudinal changes of endocrine and bone disease in adults with ?-thalassemia major receiving different iron chelators over 5 years. Ann Hematol (2016) 95:757–763.
52. EXJADE® (deferasirox) US Prescribing Information. 2013. Available from
53. Piga A, Fracchia S, Lai ME, et al. Effect of deferasirox on renal haemodynamics in patients with beta-thalassaemia: first interim analysis [abstract]. Haematologica. 2010; 95 (Suppl 2): 1798.
54. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in non-transfusion dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977.
55. Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. American Journal of Kidney Diseases 2009;54 (5):931–4.
56. Osborne V, Davies M, Layton D, Shakir AS. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug Saf (2018) 41:267–275.
57. Bayhana T, Ünal S, Ünlü O, Küçüker H, Tutal Ad, Karabulut E et al. The questioning for routine monthly monitoring of proteinuria in patients with ?-thalassemia on deferasirox chelation. HEMATOLOGY, 2017 VOL. 22, NO. 4, 248–251.
58. Origa R, Piga A, Tartaglione I et al. Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent b-thalassemia and other anemias. AJH 2018; 1-3.
59. Arandi N, Haghpanah S, Safaei S et al. Combination therapy – deferasirox and deferoxamine – in thalassemia major patients in emerging countries with limited resources. Transfusion Medicine 2015, 25, 8–12.
60. Lal, A., J. Porter, N. Sweeters, et al. 2013.Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol. Dis. 50: 99–104.
61. Cassinerio, E., N. Orofino, A. Roghi, et al. 2014. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation n in thalassemia major. Blood Cells Mol. Dis. 53: 164–167.
62. Aydinok, Y., A. Kattamis, M.D. Cappellini, et al. 2015. Effects of deferasirox–deferoxamine onmyocardial and liver iron in patients with severe transfusional iron overload. Blood 125: 3868–3877.
63. Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Exp Rev Clinic Pharmacol 2018; 11 (6): 641–650.
64. Farmaki, K., I. Tzoumari & C. Pappa. 2011. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol. Dis. 47: 33–40.
65. Totadri, S., D. Bansal, P. Bhatia, et al. 2015. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with ?-thalassemia major: a prospective, single center, open-label study. Pediatr. Blood Cancer 62: 1592–1596.
66. Elalfy, M.S., A.M. Adly, Y. Wali, et al. 2015. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur. J. Haematol. 95: 411–420.
67. Karami H, Kosaryan M, Amree Ah et al. Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion dependent ?-thalassemia major. Clinics and Practice 2017;7 (912): 11-14.
68. Parakh N, Chandra J, Sharma S et al. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With b-Thalassemia Major: An Experience From North India. J Pediatr Hematol Oncol 2017;39: 209–213.
69. Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, De Franceschi L, Forni GL. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25222. [Epub ahead of print].
70. Inati A, kahale M, Sbeiti N, Cappellini MD, Taher AT, kousa S, Nasr T, Musalem KM, Abbas HA, porter J. One?year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 2017; 64: 188-196.
71. Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, Ozudogru, ertem M. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and E?cacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with ?-Thalassemia Major. Biol Blood Marrow Transplant 24 (2018) 608–632.
72. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833-44.
73. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485-93.
74. Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016; 57:23-9.
75. Calvaruso G, Vitrano A, Di Maggio R, Lai E, Colletta G, Quota A, et al. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. Am J Hematol. 2015;90(7):634-8.
76. Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT): Thalassaemia International Federation, Nicosia, Cyprus; 2013.
77. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-29.
78. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
79. Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res. 2014; 23(8):2277-88.
80. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-17.
81. Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia (Review). Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD012349. DOI: 10.1002/14651858.CD012349.pub2.
82. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-76.
83. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-8.
84. Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92(5):420-8.
85. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta thalassemia. Blood. 2010; 115(12): 2364-2371.
86. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96(1): 48-54.
87. Pennell DJ, Porter JB, Piga A et al. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015; 90(2):91-6.

Similar Articles

You may also start an advanced similarity search for this article.